Clinical Commander

Back to dossier
cardio.dvt.recurrent-on-anticoagulation.v1PRODUCTION
cardio.dvt.recurrent-on-anticoagulation.v1

Recurrent DVT on therapeutic anticoagulation (treatment failure)

cardiologyacuteadult
Hard-required inputs
0 / 9
Care setting:

Encounter flow

11/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Recurrent DVT on therapeutic AC = breakthrough VTE; mandatory adherence + drug-level workup + occult cancer screen + targeted thrombophilia (APS focus); treatment options include AC class switch, intensity escalation, or IVC filter only if AC contraindicated; route to cardio.dvt.core.v1 for diagnostic arc

Inputs
1
Actions
0
Advance rule
Set
Advance when

breakthrough VTE confirmed and root-cause workup initiated

Patient inputs (9)

Recent age-appropriate screening status drives decision for low-threshold CT chest/abdomen/pelvis (occult cancer is a leading driver of breakthrough VTE)

Prior APS dx, miscarriages, livedo, or unexplained arterial events shift suspicion toward APS — highest-yield thrombophilia workup

Older patients higher cancer risk and more likely to have absorption + drug-interaction issues

Specific agent (apixaban/rivaroxaban/edoxaban/warfarin/LMWH), dose, frequency, duration must be confirmed; many "failures" are actually subtherapeutic doses for weight or renal function

Adherence is the single most common cause of "breakthrough" VTE; must be documented before invoking treatment failure

Drug-level testing: anti-Xa for DOAC/LMWH (chromogenic anti-Xa calibrated for the specific agent), INR for warfarin; subtherapeutic level reframes the case as adherence/dosing rather than treatment failure

Anemia or thrombocytopenia complicate AC; new anemia may signal occult cancer or bleeding

Confirm new DVT location and burden; differentiate new thrombus from chronic residual

eGFR for AC dose adjustment; cancer + chemotherapy + age can produce occult AKI affecting DOAC clearance

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (5)

5 need judgement
  • informationallife_threateningmassive_pe_on_therapeutic_ac
    Hemodynamically unstable PE with hypotension or shock in patient on documented therapeutic AC ≥4 weeks
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningphlegmasia_breakthrough_dvt_on_ac
    Phlegmasia cerulea dolens developing in patient on therapeutic AC — limb-threatening AC failure
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveretrapped_clot_post_ivc_filter
    Patient with prior IVC filter develops new DVT or has trapped clot demonstrated on imaging — filter complication or AC failure
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverethrombophilia_trigger_identification_aps_triple_positive
    Triple-positive antiphospholipid panel (lupus anticoagulant + anti-cardiolipin + anti-β2GP1) confirmed at 12 weeks in patient with breakthrough VTE on DOAC
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereoccult_cancer_found_on_breakthrough_workup
    New cancer diagnosis found during workup of breakthrough VTE on AC
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

ENTRYrequiredDrives risk stratification
Loading…

Recommended regimen

Recurrent DVT on therapeutic AC — switch class, escalate intensity, or APS-mandated warfarin (ACCP 2021 / ISTH 2024)
axis: recurrent_dvt_on_ac_treatment_failure_phenotype
Selected axis "Recurrent DVT on therapeutic AC — switch class, escalate intensity, or APS-mandated warfarin (ACCP 2021 / ISTH 2024)" by default fallback (first axis)
  • enoxaparin
    first line
    lmwh
    1 mg/kg SC BID; escalate to 1.5 mg/kg BID short-term for severe breakthrough; reduce to 1 mg/kg daily if CrCl <30 • SC • BID × ≥1 month then reassess
    triggers: breakthrough_vte_on_doac, doac_adherence_concerns, true_treatment_failure_doac
    ACCP 2021 (PMID 34352295) — switch DOAC to LMWH for breakthrough VTE; LMWH has guaranteed bioavailability and dose-response; LITE-2 (Lee 2024) supports increased-dose LMWH for breakthrough; ASH 2020 (PMID 33007077)
    rxcui 67108
  • dalteparin
    first line
    lmwh
    200 IU/kg SC daily × 1 month → 150 IU/kg SC daily • SC • daily × ≥1 month
    triggers: breakthrough_vte_on_doac_with_known_cancer_driver, lmwh_alternative_to_enoxaparin
    CLOT (Lee NEJM 2003 PMID 12853587) — dalteparin first-line for cancer-VTE; if breakthrough is cancer-driven, switch to dalteparin per ISTH 2022
    rxcui 67109
  • warfarin
    first line
    vitamin_k_antagonist
    5 mg daily; INR target 2-3 (target 3-4 if recurrent on therapeutic warfarin) • PO • daily
    triggers: triple_positive_aps_confirmed, breakthrough_vte_on_doac_in_aps_patient, mechanical_valve_with_breakthrough
    TRAPS (Pengo Blood 2018 PMID 30196097) — rivaroxaban inferior to warfarin in triple-positive APS (early stop for excess thromboembolism); RAPS (Cohen Lancet Haematol 2016 PMID 27932287) — rivaroxaban inferior in APS; ISTH 2024 — warfarin INR 2-3 mandatory for APS-VTE
    rxcui 11289
  • apixaban
    second line
    doac_factor_xa_direct
    10 mg BID × 7 d → 5 mg BID; consider 10 mg BID extended if breakthrough on standard dose without APS • PO • BID
    triggers: breakthrough_vte_on_warfarin_subtherapeutic_inr, breakthrough_vte_on_lmwh_with_adherence_difficulty, no_aps
    AMPLIFY (Agnelli NEJM 2013 PMID 23808982); switch from warfarin to DOAC if subtherapeutic INR was the cause; avoid if APS
    rxcui 1364430
  • rivaroxaban
    second line
    doac_factor_xa_direct
    15 mg BID × 21 d → 20 mg daily with food • PO • BID then daily
    triggers: breakthrough_vte_on_warfarin_subtherapeutic_inr, no_aps, no_known_drug_interactions
    EINSTEIN-DVT (Bauersachs NEJM 2010 PMID 21128814); avoid if APS — TRAPS / RAPS data
    rxcui 1114195
  • heparin
    rescue
    unfractionated_heparin
    80 U/kg bolus + 18 U/kg/h infusion targeting aPTT 1.5-2.5× • IV • continuous
    triggers: hemodynamically_unstable_breakthrough_pe, severe_renal_impairment_lmwh_unsafe, planned_invasive_procedure
    Reversibility with protamine; rapid onset; preferred in hemodynamic instability or peri-procedural (ACCP 2021)
    rxcui 235473

outpatient playbook — drug actions (1)

  1. 1. maintenance LMWH / warfarin / DOAC per APS / cancer / no-trigger phenotype
    rxcui 67108
    agent and dose per phenotype • SC or PO • as scheduled
    trigger: Long-term indefinite AC after breakthrough VTE
    ACCP 2021 indefinite AC after second VTE

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: New unilateral leg swelling/pain in patient on therapeutic-dose AC ≥4 weeks → confirm DVT and classify as breakthrough VTE; Compression US confirms new DVT (different segment or new thrombus extension) in patient on documented therapeutic AC; Documented breakthrough VTE while on therapeutic AC ≥4 weeks — treatment failure pathway initiated; root cause analysis mandatory.

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Recurrent DVT on therapeutic anticoagulation (treatment failure)** (cardio.dvt.recurrent-on-anticoagulation.v1).
Scope: Recurrent DVT on therapeutic AC = breakthrough VTE; mandatory adherence + drug-level workup + occult cancer screen + targeted thrombophilia (APS focus); treatment options include AC class switch, intensity escalation, or IVC filter only if AC contraindicated; route to cardio.dvt.core.v1 for diagnostic arc

No severity triggers fired against current inputs.

Plan

Regimen axis: **Recurrent DVT on therapeutic AC — switch class, escalate intensity, or APS-mandated warfarin (ACCP 2021 / ISTH 2024)**.
1. enoxaparin 1 mg/kg SC BID; escalate to 1.5 mg/kg BID short-term for severe breakthrough; reduce to 1 mg/kg daily if CrCl <30 SC BID × ≥1 month then reassess (lmwh, first line) — ACCP 2021 (PMID 34352295) — switch DOAC to LMWH for breakthrough VTE; LMWH has guaranteed bioavailability and dose-response; LITE-2 (Lee 2024) supports increased-dose LMWH for breakthrough; ASH 2020 (PMID 33007077)
2. dalteparin 200 IU/kg SC daily × 1 month → 150 IU/kg SC daily SC daily × ≥1 month (lmwh, first line) — CLOT (Lee NEJM 2003 PMID 12853587) — dalteparin first-line for cancer-VTE; if breakthrough is cancer-driven, switch to dalteparin per ISTH 2022
3. warfarin 5 mg daily; INR target 2-3 (target 3-4 if recurrent on therapeutic warfarin) PO daily (vitamin_k_antagonist, first line) — TRAPS (Pengo Blood 2018 PMID 30196097) — rivaroxaban inferior to warfarin in triple-positive APS (early stop for excess thromboembolism); RAPS (Cohen Lancet Haematol 2016 PMID 27932287) — rivaroxaban inferior in APS; ISTH 2024 — warfarin INR 2-3 mandatory for APS-VTE
4. apixaban 10 mg BID × 7 d → 5 mg BID; consider 10 mg BID extended if breakthrough on standard dose without APS PO BID (doac_factor_xa_direct, second line) — AMPLIFY (Agnelli NEJM 2013 PMID 23808982); switch from warfarin to DOAC if subtherapeutic INR was the cause; avoid if APS
5. rivaroxaban 15 mg BID × 21 d → 20 mg daily with food PO BID then daily (doac_factor_xa_direct, second line) — EINSTEIN-DVT (Bauersachs NEJM 2010 PMID 21128814); avoid if APS — TRAPS / RAPS data
6. heparin 80 U/kg bolus + 18 U/kg/h infusion targeting aPTT 1.5-2.5× IV continuous (unfractionated_heparin, rescue) — Reversibility with protamine; rapid onset; preferred in hemodynamic instability or peri-procedural (ACCP 2021)

Setting playbook (outpatient) — Long-term indefinite-AC management after breakthrough VTE; APS-driven warfarin if confirmed; cancer-VTE pathway if cancer-driven; ongoing surveillance for recurrence and bleeding
7. maintenance LMWH / warfarin / DOAC per APS / cancer / no-trigger phenotype agent and dose per phenotype SC or PO as scheduled — Long-term indefinite AC after breakthrough VTE (ACCP 2021 indefinite AC after second VTE)

Non-pharmacologic actions:
- Adherence support ongoing
- Bleed-risk modification (BP, alcohol, NSAID avoidance)
- Cancer treatment continuation if applicable

AVOID / contraindication checks:
- Doac_avoid_active_bleeding (FDA labels)
- Doac_avoid_in_triple_positive_aps_use_warfarin (TRAPS PMID 30196097; ISTH 2024)
- Apixaban_avoid_egfr_below_15 (FDA label)
- Rivaroxaban_avoid_egfr_below_30 (FDA label)
- Lmwh_dose_reduce_if_crcl_below_30 (ACCP 2021)
- Hold_AC_if_active_bleeding_or_severe_thrombocytopenia (ASH 2020)
- Decision:ivc_filter_only_if_absolute_AC_contraindication (PREPIC2 PMID 25919526)
- Decision:indefinite_AC_after_second_vte_event (ACCP 2021)
- Decision:occult_cancer_screening_threshold_low_in_breakthrough_VTE (SOME framing)

Monitoring

Regimen monitoring:
- anti xa calibrated for doac or lmwh at switch and 1 2 weeks (ACCP 2021)
- inr q week during warfarin initiation then q 4 weeks target 2-3 (ACCP 2021)
- cbc q week x first month then monthly (ASH 2020)
- creatinine q3mo for dose adjustment (FDA labels)
- aps panel lupus anticoagulant acl anti b2gp1 at acute then repeat at 12 weeks (ISTH 2024)
- cancer imaging per screening status low threshold for ct chest abdomen pelvis
- bleeding screen at each visit

Setting (outpatient) monitoring:
- Quarterly clinical + lab
- Annual reassessment of indefinite-AC tradeoff

Follow-up plan: Indefinite AC after second VTE event regardless of provoking factor (ACCP 2021); APS triple-positive lifelong warfarin; cancer-driven recurrence → switch to cancer-VTE pathway with cancer-active indefinite AC; share decision with patient on bleed-vs-recurrence tradeoff
- Close-out criterion: extended/indefinite AC plan finalized

Monitoring phase: Anti-Xa or INR documented at switch and 1-2 weeks; CBC + BMP at week 1 then monthly; APS confirmatory testing at 12 weeks if initial positive; cancer surveillance per workup findings; recurrent VTE symptoms

Disposition

Current setting: outpatient — Long-term indefinite-AC management after breakthrough VTE; APS-driven warfarin if confirmed; cancer-VTE pathway if cancer-driven; ongoing surveillance for recurrence and bleeding

Disposition criteria:
- Long-term indefinite AC continuation; cross-link to cancer-VTE engine if cancer-driven

Escalation triggers (move to higher acuity):
- New VTE → re-evaluate AC strategy
- Major bleed → hold + reverse + reassess

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Hemodynamically unstable PE with hypotension or shock in patient on documented therapeutic AC ≥4 weeks
- [LIFE_THREATENING] Phlegmasia cerulea dolens developing in patient on therapeutic AC — limb-threatening AC failure
- [SEVERE] Patient with prior IVC filter develops new DVT or has trapped clot demonstrated on imaging — filter complication or AC failure

Citations

- ACCP/CHEST 2021 Antithrombotic + ASH 2020 VTE Treatment + ISTH 2024 antiphospholipid + TRAPS / RAPS for APS-VTE [PMID:34352295](https://pubmed.ncbi.nlm.nih.gov/34352295/)
- Cited evidence (PMID 33007077) [PMID:33007077](https://pubmed.ncbi.nlm.nih.gov/33007077/)
- Cited evidence (PMID 30196097) [PMID:30196097](https://pubmed.ncbi.nlm.nih.gov/30196097/)
- Cited evidence (PMID 27932287) [PMID:27932287](https://pubmed.ncbi.nlm.nih.gov/27932287/)
- Cited evidence (PMID 23808982) [PMID:23808982](https://pubmed.ncbi.nlm.nih.gov/23808982/)

Last reconciled with current guidelines: 2026-05-14.
References